Abstract
Ribosome display is a powerful cell-free technology to select a desired antibody together with its encoding mRNA. In this study, a human single-chain variable fragment (scFv) library was generated from the peripheral blood lymphocyte RNA of 10 ovarian cancer patients and then panned against bead-conjugated human PlGF, a protein that may contribute to the growth and metastasis of ovarian cancer. A selected scFv antibody was evaluated by Western blot and its affinity constant to the PlGF was determined by noncompetitive enzyme immunoassay. This study highlights the ribosomal display technology for the selection of human antibody from patient-derived gene pools.
Keywords: Ribosome display, In vitro selection, Antibody engineering, PlGF, scFv, Ovarian cancer
Protein & Peptide Letters
Title: Ribosome Display and Selection of Human Anti-Placental Growth Factor scFv Derived from Ovarian Cancer Patients
Volume: 17 Issue: 5
Author(s): Fang Li, Pingping Su, Chao Lin, Hong Li, Jiajing Cheng and Donglu Shi
Affiliation:
Keywords: Ribosome display, In vitro selection, Antibody engineering, PlGF, scFv, Ovarian cancer
Abstract: Ribosome display is a powerful cell-free technology to select a desired antibody together with its encoding mRNA. In this study, a human single-chain variable fragment (scFv) library was generated from the peripheral blood lymphocyte RNA of 10 ovarian cancer patients and then panned against bead-conjugated human PlGF, a protein that may contribute to the growth and metastasis of ovarian cancer. A selected scFv antibody was evaluated by Western blot and its affinity constant to the PlGF was determined by noncompetitive enzyme immunoassay. This study highlights the ribosomal display technology for the selection of human antibody from patient-derived gene pools.
Export Options
About this article
Cite this article as:
Li Fang, Su Pingping, Lin Chao, Li Hong, Cheng Jiajing and Shi Donglu, Ribosome Display and Selection of Human Anti-Placental Growth Factor scFv Derived from Ovarian Cancer Patients, Protein & Peptide Letters 2010; 17 (5) . https://dx.doi.org/10.2174/092986610791112729
DOI https://dx.doi.org/10.2174/092986610791112729 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanocarriers to Solid Tumors: Considerations on Tumor Penetration and Exposure of Tumor Cells to Therapeutic Agents
Current Pharmaceutical Biotechnology Modulation of the Immune Response by Targeting Endothelial Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Stem Cell Factor Receptor/c-Kit as a Drug Target in Cancer
Current Cancer Drug Targets Silybin and Silymarin - New and Emerging Applications in Medicine
Current Medicinal Chemistry Identification and Targeting of Tumor Escape Mechanisms: A New Hope for Cancer Therapy?
Current Pharmaceutical Design Boronated DNA-Binding Compounds as Potential Agents for Boron Neutron Capture Therapy
Mini-Reviews in Medicinal Chemistry PARP Inhibitors in Epithelial Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Biological Applications of ZnO Nanoparticles
Current Molecular Imaging (Discontinued) Effects of Salinomycin on Cancer Stem Cell in Human Lung Adenocarcinoma A549 Cells
Medicinal Chemistry Lessons in Medical Record Abstraction from the Prostate, Lung, Colorectal, and Ovarian (PLCO) National Screening Trial
Reviews on Recent Clinical Trials Potential of Plant-Derived Natural Products in the Treatment of Leukemia and Lymphoma
Current Drug Targets The Role of Anti-LeY Antibody in the Downregulation of MAPKs/COX-2 Pathway in Gastric Cancer
Current Drug Targets Prostate Cancer, miRNAs, Metallothioneins and Resistance to Cytostatic Drugs
Current Medicinal Chemistry From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?
Current Cancer Drug Targets Desensitization for Drug Hypersensitivity to Chemotherapy and Monoclonal Antibodies
Current Pharmaceutical Design Is HE4 Superior over CA-125 in the Follow-up of Patients with Epithelial Ovarian Cancer?
Current Drug Targets Apoptotic Effects of N-(2-Hydroxyphenyl)-2-Propylpentanamide on U87-MG and U-2 OS Cells and Antiangiogenic Properties
Anti-Cancer Agents in Medicinal Chemistry STING Activation and its Application in Immuno-Oncology
Current Topics in Medicinal Chemistry Modulation of Aquaporins by Dietary Patterns and Plant Bioactive Compounds
Current Medicinal Chemistry Drugs Acting on the Beta Isoform of Human Topoisomerase II (p180)
Current Medicinal Chemistry - Anti-Cancer Agents